New Drug soon for Hepatitis C, 20th July 2016

The U.S. Food and Drug Administration has approved Epclusa (A fixed dose combination tablet containing Sofosbuvir and Velpatasvir) to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis. For patients with decompensated cirrhosis, Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination and is the first to treat all six major forms of HCV.

Comments are closed.